General
J&J, Imerys Appeal to Reverse the $117 M Talc Verdict
Defendants Johnson & Johnson and Imerys, its talc supplier, have appealed the $117 million New Jersey verdict announced earlier this month and deny the presence of …
A 2015 Zimmer Hip Replacement Lawsuit Verdict Reversed
The first Zimmer Durom Cup Hip Replacement lawsuit, which was tried before Judge Amy D. Hogue in L.A. County Superior Court in August 2015, resulted…
PPI Litigation Plaintiffs Urge Early Bellwether Trial Dates
With the expected rise in the size of the proton pump inhibitor MDL litigation and chances of the number doubling or even tripling in the coming years, the Plaintiffs’ Co-Lead Counsel submitted a written request on April 27 before presiding U.S.…
Roundup Trial Deadlines Pushed As Settlement Talks Continue
The U.S. District Judge Vince Chhabria, presiding over all Roundup lawsuits, agreed to push back several deadlines in the litigation and vacated a trial set to begin later…
The first win for 'Xarelto Plaintiff'
The first Philadelphia Xarelto bellwether trial, convened in the Philadelphia's Complex Litigation Center, not only went in favor of the plaintiff but also was the first win for a '…
Opioid MDL Approved; Purdue May Opt Global Settlement
On December 5, 2017, a formal nod came in for the formation of Opioid MDL: 2804 by the U.S. Judicial Panel on Multidistrict Litigation. To promote the just and efficient conduct of…
Bayer AG Reaches Deal On Major Portion Of Roundup Lawsuits
<p>Actos (pioglitazone) is an oral diabetes medicine of the thiazolidinedione (TZD) class used to treat Type 2 diabetes. Actos is manufactured by Japanese pharma giant Takeda Pharmaceutical and marketed by Eli Lilly, one of the largest drug…
Opioids Prescription Violations Costs CVS Subsidiary $15.3M
The U.S. Attorney for Colorado, Jason R. Dunn, announced that Omnicare Inc., a subsidiary of CVS Health, has agreed to compensate $15.3 million in penalties to settle allegations of dispensing…
Plaintiffs Now Opposing Centralization of Stockert 3T Cases
Abilify (aripiprazole) is an atypical antipsychotic developed by Otsuka Pharmaceutical Co., Ltd. In 1999, Otsuka partnered with Bristol-Myers Squibb (BMS) to complete development, obtain approvals, and market aripiprazole in the U.S. In…
Another Onglyza case filed
A product liability lawsuit was filed against Bristol-Myers Squibb and AstraZeneca by a woman who suffered heart failure and other severe cardiovascular complications alleging to be side effects of the saxagliptin-based diabetes drugs,…